These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21912063)

  • 1. Concurrent autoimmune hepatitis and grave's disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy.
    Trikudanathan GV; Ahmad I; Israel JL
    Saudi J Gastroenterol; 2011; 17(5):348-52. PubMed ID: 21912063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
    Baker RD; Dee D; Baker SS
    J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Autoimmune hepatitis and membranous glomerulonephritis under immune therapy in chronic hepatitis C].
    Paparoupa M; Huy Ho NA; Schuppert F
    Dtsch Med Wochenschr; 2016 May; 141(10):709-11. PubMed ID: 27176065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.
    Gheorghe L; Grigorescu M; Iacob S; Damian D; Gheorghe C; Iacob R; Simionov I; Vadan R; Parvulescu I; Bancila I
    Rom J Gastroenterol; 2005 Jun; 14(2):109-15. PubMed ID: 15990928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fulminant autoimmune hepatitis after successful interferon treatment in an HIV-HCV co-infected patient.
    Coriat R; Podevin P
    Int J STD AIDS; 2008 Mar; 19(3):208-10. PubMed ID: 18397566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.
    Urquijo JJ; Diago M; Boadas J; Planas R; Solá R; Del Olmo JA; Crespo J; Erdozaín JC; Antón MD; Arocena C; Suarez D; Giné J; Barrera JM; Gracia-Samaniego J; Perez R; Dalmau B; Montoro M
    Ann Hepatol; 2013; 12(1):30-5. PubMed ID: 23293191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo autoimmune hepatitis subsequent to switching from type 2b to type 2a alpha-pegylated interferon treatment for recurrent hepatitis C after liver transplantation: report of a case.
    Takeishi K; Shirabe K; Toshima T; Ikegami T; Morita K; Fukuhara T; Motomura T; Mano Y; Uchiyama H; Soejima Y; Taketomi A; Maehara Y
    Surg Today; 2011 Jul; 41(7):1016-9. PubMed ID: 21748625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment.
    Kogure T; Ueno Y; Fukushima K; Nagasaki F; Inoue J; Kakazu E; Matsuda Y; Kido O; Nakagome Y; Kimura O; Obara N; Wakui Y; Iwasaki T; Shimosegawa T
    World J Gastroenterol; 2007 Aug; 13(32):4394-7. PubMed ID: 17708618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial.
    Jiménez-Luévano MÁ; Lerma-Díaz JM; Hernández-Flores G; Jiménez-Partida MÁ; Bravo-Cuellar A
    Ann Hepatol; 2013; 12(2):248-55. PubMed ID: 23396736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
    Helal GK; Gad MA; Abd-Ellah MF; Eid MS
    J Med Virol; 2016 Dec; 88(12):2170-2178. PubMed ID: 27183377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.
    Cornberg M; Wedemeyer H; Manns MP
    Curr Gastroenterol Rep; 2002 Feb; 4(1):23-30. PubMed ID: 11825538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).
    Halfon P; Pérusat S; Bourlière M; Bronowicki JP; Trimoulet P; Benhamou Y; Leroy V; Marcellin P; Foucher J; Penaranda G; Chêne G; Couzigou P;
    J Med Virol; 2010 Dec; 82(12):2027-31. PubMed ID: 20981789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.